SCHEMBL10165890

SCHEMBL10165890

O=C(Cc1ccc2ccccc2c1)Nc1cc2cc(-c3cc[nH]c3)ccc2cn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WNT3A P56704 1/20 0.59
DYRK1A Q13627 9/20 0.56
GSK3B P49841 8/20 0.56
WNT1 P04628 5/20 0.56
MAPK8 P45983 2/20 0.53
RIOK2 Q9BVS4 6/20 0.52
GSK3A P49840 3/20 0.52
MAPK10 P53779 3/20 0.52
HIPK1 Q86Z02 1/20 0.52
SNRK Q9NRH2 1/20 0.52
NPY5R Q15761 2/20 0.49
CLK2 P49760 1/20 0.47
CLK3 P49761 1/20 0.47
CCNB2 O95067 1/20 0.46
CCNE2 O96020 1/20 0.46
CDK1 P06493 1/20 0.46
CCNB1 P14635 1/20 0.46
CCNA2 P20248 1/20 0.46
CCNE1 P24864 1/20 0.46
CDK2 P24941 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10165889 0.86 MAPK8 (0.72) WNT3ADYRK1AGSK3BWNT1MAPK8
SCHEMBL560081 0.86 WNT3A (0.59) WNT3ADYRK1AGSK3BWNT1MAPK8
SCHEMBL12361579 0.78 WNT3A (0.57) WNT3ADYRK1AGSK3BWNT1MAPK8
SCHEMBL12303086 0.78 WNT3A (0.83) WNT3ADYRK1AGSK3BWNT1MAPK8
SCHEMBL559024 0.76 DYRK1A (0.65) WNT3ADYRK1AGSK3BWNT1MAPK8
SCHEMBL1722613 0.74 WNT3A (1.00) WNT3ADYRK1AGSK3BWNT1RIOK2
SCHEMBL10165892 0.74 GSK3B (0.47) DYRK1AGSK3BWNT1
SCHEMBL10165891 0.73 MAPK8 (0.53) DYRK1AGSK3BWNT1MAPK8
SCHEMBL559364 0.73 MAPK8 (0.70) WNT3ADYRK1AGSK3BWNT1MAPK8
SCHEMBL19517223 0.72 WNT1 (1.00) DYRK1AGSK3BWNT1MAPK8CLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035194-A1 SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS PFIZER INC. (US) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035194-A1 SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS MAPK1, SLC5A1, ATF1 WNT3A 1899/4885DYRK1A 1064/4885GSK3B 685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.